German News | TCL Sued by MPEG LA for AVC Patent Infringement


A TV manufacturer, TCL, that works closely with smart TV OS partners such as Roku is currently being sued by members of MPEG LA for patent infringement.

The complaint states that MPEG LA, a patent pool covering licenses for standards and other technology platforms, said patent owners in its AVC (Advanced Video Coding) patent portfolio license have filed patent enforcement actions in Germany against TCL Deutschland GmbH & Co. KG and TCT Mobile Germany GmbH for “infringing patents essential to the AVC/H.264 (MPEG-4 Part 10) digital video coding standard used in mobile devices, televisions and other products.”

MPEG LA alleges that TCL offers mobile phone and television products in Germany, which use patent protected AVC methods without licenses with the individual patent holders or a portfolio license that includes these patents offered by MPEG LA. The suits seek monetary damages and injunctions.


MPEG LA is the world’s leading packager and provider of one-stop licenses for standards and other technology platforms. By assisting users with implementation of their technology choices, MPEG LA offers licensing solutions that provide access to fundamental intellectual property, freedom to operate, reduced litigation risk and predictability in the business planning process. In turn, this enables inventors, research institutions and other technology owners to monetize and speed market adoption of their assets to a worldwide market while substantially reducing the cost of licensing. ​ MPEG LA licensing programs consisting of thousands of patents owned by hundreds of patent holders in nearly 100 countries with over 6,000 licensees have helped produce some of the most widely used standards in consumer electronics history, and are expanding access to other technology areas.

Print Friendly, PDF & Email
About Bob Aroture 564 Articles
Bob is a Senior Editor and Content Development Manager at Nigerian Law Intellectual Property Watch. He holds a BS degree, with a major in biochemistry. He works directly with the Newsroom Team. His focus areas are technology and innovation, and pharmaceutical technology. Email:

Be the first to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.